June 7th 2021, 1:00pm
The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.
June 7th 2021, 12:00pm
Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.
June 6th 2021, 8:00pm
After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.
June 6th 2021, 7:00pm
Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.
June 6th 2021, 5:00pm
Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.
June 5th 2021, 3:00pm
Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.
June 5th 2021, 1:00pm
The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.
April 30th 2021, 3:22pm
View the entire 2021 Extraordinary Healer® Award for Oncology Nursing virtual presentation here!
March 16th 2021, 1:00pm
An expert discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates. Each therapy type has an FDA-approved option to potentially provide patients with better outcomes and quality of life.
March 15th 2021, 1:00pm
In the field of lung cancer, a number of current studies evaluating the efficacy of adoptive cellular therapies may one day offer patients with non-small cell lung cancer a “high risk, high reward” treatment option, according to Dr. Ben Creelan of the Moffitt Cancer Center.